# Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

Source: https://onco.cc/trials/nct04851717/  
OnCo record `nct04851717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Remimazolam in childhood cancers, run by Acacia Pharma Ltd, active and no longer recruiting.

## Summary

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures is a phase 2/3 interventional study registered as NCT04851717 by Acacia Pharma Ltd, with 100 participants enrolled, started 2021-11-15 and due to reach its primary completion in 2027-10. Interventions recorded: Remimazolam.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04851717
- Phase: 2/3
- Setting: A Phase 2/3, Prospective, Open-label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Remimazolam for Intravenous Sedation in Paediatric Patients Undergoing Diagnostic and/or Therapeutic Procedures
- Sponsor: Acacia Pharma Ltd
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT04851717: https://clinicaltrials.gov/study/NCT04851717

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [Acacia Pharma](https://onco.cc/companies/acacia-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04851717.json